Drugs / Piperacillin
Piperacillin
also known as
Piperacillin Sodium · CL 227,193 · NSC-757277 · Penmalin · Peracin · PIPC · PIPC, piperacillin sodium · Piperacilina · +10 more
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | PIPRACIL | — | 1984-08-06 | fda.gov ↗ |
| Approved | US (FDA) | PIPRACIL | — | 1981-12-29 | fda.gov ↗ |
Trials 32
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT03441529 | Feb → May 2018 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT03685084 | Oct 2013 → Jan 2014 | — | Allecra | Completed | No outcome recorded |
| Phase 1 | NCT00894439 | May → Jul 2009 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02817347 | Jun 2016 → Apr 2017 | discharging ear, otitis media | Yuhan Corporation | Terminated | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07481539 | Mar 2026 → Apr 2027 expected | bacterial infectious disease | Azienda Sanitaria Universitaria Friuli Centrale | Recruiting | No outcome recorded |
| Phase 2 | NCT05753735 | Jan → Mar 2024 | pancreas disorder | Case Comprehensive Cancer Center | Terminated | No outcome recorded |
| Phase 34 trials · 1 met primary | ||||||
| Phase 3 | NCT00629135 | Nov 2005 → Aug 2011 | abscess | Hannover Medical School | Completed | No outcome recorded |
| Phase 3 | NCT00389987 | Sep 2001 → May 2004 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00229112 | Apr 2001 → Apr 2004 | — | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 3 | NCT00044759 | ? → Jan 2003 | hematopoietic and lymphoid cell neoplasm | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 414 trials | ||||||
| Phase 4 | NCT05981079 | Jul 2023 → Dec 2024 | neonatal sepsis | Shandong University | Unknown | No outcome recorded |
| Phase 4 | NCT05394298 | Jul 2022 → Jul 2024 | Enterococcus infectious disease | Andalusian Public Foundation for Health Research in Seville | Unknown | No outcome recorded |
| Phase 4 | NCT05355350 | Jul 2022 → Jul 2025 | bacterial infectious disease | Rambam Health Care Campus | Withdrawn | No outcome recorded |
| Phase 4 | NCT04948463 | Nov 2021 → Dec 2025 | neutropenia | Murdoch Childrens Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT04233996 | Jun 2019 → Dec 2021 | neutropenia | Hospital Universitari de Bellvitge | Unknown | No outcome recorded |
| Phase 4 | NCT03289351 | May 2017 → Nov 2021 | appendicitis | Phoenix Children's Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02730624 | Mar 2014 → May 2016 | infectious disease with sepsis | Sutep Jaruratanasirikul | Completed | No outcome recorded |
| Phase 4 | NCT01694069 | Sep 2012 → Sep 2013 | cystic fibrosis | West Virginia University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01897831 | Aug 2011 → Aug 2015 | respiratory tract infectious disorder, urinary tract infection | Xiangbei Welman Pharmaceutical Co., Ltd | Unknown | No outcome recorded |
| Phase 4 | NCT01198925 | Sep 2010 → Nov 2012 | infectious disease | University Hospital, Ghent | Completed | No outcome recorded |
| Phase 4 | NCT00703144 | Jun 2008 → Aug 2012 | — | University Hospital, Toulouse | Completed | No outcome recorded |
| Phase 4 | NCT00478855 | Sep 2006 → Jun 2007 | bacterial infectious disease | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00044928 | Jul 2002 → Feb 2004 | bacterial infectious disease | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00044746 | Oct 2000 → Jan 2003 | diabetes mellitus | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase not applicable8 trials | ||||||
| — | NCT06972537 | Jul 2024 → Sep 2026 overdue | pneumonia | Shandong University | Recruiting | No outcome recorded |
| — | NCT02795793 | May 2016 → May 2019 | appendicitis | Sydney Children's Hospitals Network | Unknown | No outcome recorded |
| — | NCT02840136 | Feb 2016 → Sep 2017 | cystic fibrosis | University Ghent | Terminated | No outcome recorded |
| — | NCT01923363 | Feb 2014 → Jan 2016 | obesity disorder | Loma Linda University | Completed | No outcome recorded |
| — | NCT01714570 | Nov 2012 → Mar 2014 | neutropenia | Chinese PLA General Hospital | Completed | No outcome recorded |
| — | NCT01697059 | Sep 2012 → May 2015 | appendicitis | Rhode Island Hospital | Completed | No outcome recorded |
| — | NCT01805856 | Nov 2010 → May 2012 | parathyroid gland disorder, thyroid gland disorder | Ito Hospital | Completed | No outcome recorded |
| — | NCT00924742 | Mar → Apr 2009 | — | Tri-Service General Hospital (TSGH) | Completed | No outcome recorded |
| Comparator or background therapy24 trials | ||||||
| Phase 0 | NCT02099240 Comparator | Mar 2014 → Nov 2018 | osteomyelitis | University of Louisville | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT05060419 Comparator | Oct 2021 → Apr 2022 | acute pyelonephritis | Qilu Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT03485950 Comparator | May 2018 → May 2021 | infectious disease | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT03435900 Comparator | Feb → Jul 2018 | appendicitis | Herlev Hospital | Completed | Met primary |
| Phase 2/3 | NCT01796717 Comparator | Mar 2012 → Nov 2016 | bacterial pneumonia | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT04042077 Comparator | Sep 2019 → Oct 2020 | — | Menarini Group | Terminated | Met primary |
| Phase 3 | NCT03687255 Comparator | Sep 2018 → Jan 2020 | urinary tract infection | Allecra | Completed | Met primary |
| Phase 3 | NCT03583333 Comparator | Sep 2018 → Jul 2022 | bacterial pneumonia | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 3 | NCT03006679 Comparator | Aug 2018 → Jun 2020 | bacterial pneumonia | Melinta Therapeutics, Inc. | Withdrawn | No outcome recorded Stop: Business |
| Phase 3 | NCT02493764 Comparator | Nov 2015 → Apr 2019 | bacterial pneumonia | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 3 | NCT02166476 Comparator | Nov 2014 → Apr 2016 | acute pyelonephritis | Melinta Therapeutics, Inc. | Completed | Met primary |
| Phase 3 | NCT01853982 Comparator | Jun → Nov 2013 | — | Merck & Co., Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT02619149 Comparator | Mar 2009 → Dec 2017 | acute cholecystitis | Karolinska Institutet | Completed | No outcome recorded |
| Phase 3 | NCT00402727 Comparator | Sep 2006 → Jun 2008 | abscess, skin infection, ulcer disease | Bayer | Completed | Met primary |
| Phase 3 | NCT00253955 Comparator | Jun 2003 → May 2007 | pneumonia | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00003805 Background | Nov 1997 → Jun 2000 | bone marrow disorder, cancer of unknown primary site, childhood malignant neoplasm, infectious disease +3 | European Organisation for Research and Treatment of Cancer - EORTC | Completed | No outcome recorded |
| Phase 4 | NCT07556107 Comparator | Jun 2026 → Jun 2028 expected | acute kidney injury, infectious disease with sepsis | Bassett Healthcare | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06184659 Comparator | Jun 2025 → Jun 2028 expected | infectious disease with sepsis | Scandinavian Critical Care Trials Group | Recruiting | No outcome recorded |
| Phase 4 | NCT03891433 Comparator | Apr 2019 → Dec 2024 | Klebsiella pneumonia, bacterial urinary tract infection, escherichia coli infection | Universidad del Norte | Suspended | No outcome recorded |
| Phase 4 | NCT00634166 Background | Sep 2007 → Dec 2013 | — | Mylan Inc. | Terminated | No outcome recorded |
| Phase 4 | NCT00488189 Comparator | May 2007 → Feb 2008 | bacterial infectious disease | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| — | NCT04394182 Background | Apr → Dec 2020 | cytokine release syndrome, viral pneumonia | Fundacion GenesisCare | Suspended | No outcome recorded Stop: Enrollment |
| — | NCT03765645 Comparator | Oct 2018 → Aug 2020 | — | Institute of Liver and Biliary Sciences, India | Completed | No outcome recorded |
| — | NCT01714557 Comparator | Sep 2012 → Sep 2014 | disease related to hematopoietic stem cell transplant, neutropenia | Chinese PLA General Hospital | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2020-05-06 | Merck Sharp & Dohme LLC | Results Results of Phase 3 Trial Evaluating the Efficacy and Safety of Merck’s RECARBRIO™ (Imipenem, Cilastatin, and Relebactam) Versus Piperacillin and Tazobactam in Adult Patients with HABP/VABP Now Available merck.com ↗
RECARBRIO met its primary and key secondary endpoints, demonstrating non-inferiority compared to PIP/TAZ. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-05-06 | Merck Sharp & Dohme LLC | Results of Phase 3 Trial Evaluating the Efficacy and Safety of Merck’s RECARBRIO™ (Imipenem, Cilastatin, and Relebactam) Versus Piperacillin and Tazobactam in Adult Patients with HABP/VABP Now Available merck.com ↗ |
Evidence & citations 22 cited values
Every value below carries the sentence it was read from. 57 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Piperacillin | “This is an antibiotic intervention study to determine the value of using piperacillin/tazobactam in reducing the cases of ESBL producing E. coli or K. pneumoniae colonization...” NCT00488189 ↗52“Controlled group will receive piperacillin/tazobactam of 4.5g Q6h, intermittent infusion for 30 minutes” NCT01796717 ↗ “4 g piperacillin/500 mg tazobactam and 1 g metronidazole administered intravenously during surgery” NCT03435900 ↗ “4000 mg Piperacillin and 500 mg Tazobactam powder FDC provided in a single vial” NCT03583333 ↗ “Piperacillin/tazobactam (isolates sensitive to ampicillin) 4 g/8h (i.v.)” NCT05394298 ↗ “Piperacillin Sodium and Sulbactam Sodium for Injection(2:1)” NCT01897831 ↗ “With intravenous Piperacillin with Tazobactam (Tazocin)” NCT02795793 ↗ “Piperacillin*” NCT02099240 ↗ |
| Known as | CL 227,193 | ChEMBL registry synonym — accepted as the source's own label CHEMBL702 ↗ |
| Known as | NSC-757277 | ChEMBL registry synonym — accepted as the source's own label CHEMBL702 ↗ |
| Known as | Penmalin | ChEMBL registry synonym — accepted as the source's own label CHEMBL702 ↗ |
| Known as | Peracin | ChEMBL registry synonym — accepted as the source's own label CHEMBL702 ↗ |
| Known as | PIPC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01805856 ↗ |
| Known as | PIPC, piperacillin sodium | “PIPC, piperacillin sodium” NCT01805856 ↗ |
| Known as | Piperacilina | ChEMBL registry synonym — accepted as the source's own label CHEMBL702 ↗ |
| Known as | Piperacillin (as sodium) | ChEMBL registry synonym — accepted as the source's own label CHEMBL702 ↗ |
| Known as | Piperacillin anhydrous | ChEMBL registry synonym — accepted as the source's own label CHEMBL702 ↗ |
| Known as | Piperacillin hydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL702 ↗ |
| Known as | Piperacillin monohydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL702 ↗ |
| Known as | Piperacillin Sodium | “'Topical Antimicrobial/Antifungal Medications' Various topical antimicrobials and antifungals include: Bacitracin; Amphotericin B; Silver Sulfadiazine; Cefazolin; Vancomycin;...” NCT00634166 ↗3“Piperacillin Sodium and Tazobactam Sodium for Injection (Bonda) 4.5g administered four times a day (QID), with each infusion lasting for 4 hours.” NCT06972537 ↗ “Drug: PIPC piperacillin sodium” NCT01805856 ↗ |
| Known as | Piperacillin sodium component of zosyn | ChEMBL registry synonym — accepted as the source's own label CHEMBL702 ↗ |
| Known as | Piperacillin sodium salt | ChEMBL registry synonym — accepted as the source's own label CHEMBL702 ↗ |
| Known as | Piperacilline | ChEMBL registry synonym — accepted as the source's own label CHEMBL702 ↗ |
| Known as | Pipracil | ChEMBL registry synonym — accepted as the source's own label CHEMBL702 ↗ |
| Known as | Pipril | ChEMBL registry synonym — accepted as the source's own label CHEMBL702 ↗ |
| Known as | T-1220 | ChEMBL registry synonym — accepted as the source's own label CHEMBL702 ↗ |
| Action | Inhibit | “Piperacillin sodium and sulbactam sodium for injection (2:1) plays a therapeutic role by the former inhibiting bacterial cell wall synthesis by irreversible competitive...” NCT01897831 ↗ |
| Modality | Small molecule | “combination beta-lactam-beta-lactamase inhibitor” NCT05355350 ↗ |
| Route | Intravenous | “Patients receive piperacillin/tazobactam IV over 20-30 minutes every 6 hours.” NCT00003805 ↗ |